Heart-1 Gene Therapy Trial Pauses Enrollment

A phase 1 gene editing trial in patients with heterozygous familial hypercholesterolemia and atherosclerotic CVD was paused after abnormal lab results were seen.

Related Keywords

New Zealand ,United States ,Canada ,United Kingdom ,American ,Sekar Kathiresan ,Health Canada ,Verve Therapeutics Inc ,Devices Safety Authority ,Drug Administration ,Regulatory Agency ,Scientific Sessions Of The American Heart Association ,Verve Therapeutics ,Scientific Sessions ,American Heart Association ,United Kingdom Medicines ,New Zealand Medicines ,Medical Devices Safety ,New Drug Application ,Genomics Genomic Medicine ,Cv Risk ,Cardiovascular Risk ,V Risk Factors ,Cardiovascular Risk Factors ,Cardiovascular Risk Management ,Patient Safety ,Lipids ,Ipid Management ,Heart ,Arrhythmia ,Atherosclerotic Heart Disease ,Therosclerotic Cardiovascular Disease ,Oronary Heart Disease ,Schemic Heart Disease ,Coronary Artery Disease ,Gene Editing ,Genetic Editing ,